Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 783-786

  Ekblad, Lars ^a   Johnsson, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Cetuximab; Colorectal cancer; Drug resistance; Epidermal growth factor receptor; Oxaliplatin; S1 colon cancer cell line

Indexed keywords

CETUXIMAB; OXALIPLATIN; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL GROWTH; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 84858786876     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A and Koralewski P: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671, 2009.
2. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R and Cheadle JP: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377: 2103-2114, 2011.
3. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O and Christoffersen T: Phase III Trial of Cetuximab with Continuous or Intermittent Fluorouracil, Leucovorin and Oxaliplatin (Nordic FLOX) Versus FLOX alone in Firstline Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study. J Clin Oncol, In press.
4. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ and Zalcberg JR: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765, 2008.
5. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T and Bates SE: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59: 8-13, 1999. (Pubitemid 29062946)
6. Ekblad L, Kjellström J and Johnsson A: Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells. Anticancer Drugs 21: 523-531, 2010.
7. Yamatodani T, Ekblad L, Kjellén E, Johnsson A, Mineta H and Wennerberg J: Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol 135: 395-402, 2009.
8. Welinder C and Ekblad L: Coomassie staining as loading control in Western blot analysis. J Proteome Res 10: 1416-1419, 2011.
9. Dickstein BM, Wosikowski K and Bates SE: Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol Cell Endocrinol 110: 205-211, 1995.
10. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P and Hagan MP: Epidermal growth factor and ionizing radiation upregulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 159: 439-452, 2003. (Pubitemid 36397765)
11. Ametller E, Garcia-Recio S, Pastor-Arroyo EM, Callejo G, Carbo N, Gascon P and Almendro V: Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death. Cancer Biol Ther 11: 4-13, 2011.
12. Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, Tassone P, Abbruzzese A, Tagliaferri P and Caraglia M: Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). Eur J Cancer 46: 1703-1711, 2010.
13. Prewett M, Deevi DS, Bassi R, Fan F, Ellis LM, Hicklin DJ and Tonra JR: Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin Cancer Res 13: 7432-7440, 2007.